Enterome to present updates on EO2401, its first-in-class OncoMimics therapeutic cancer vaccine targeting solid tumors, at ESMO Congress 2022
Enterome is evaluating EO2401 in Phase 1/2 clinical trials in recurrent glioblastoma (ROSALIE) and adrenocortical malignancies (SPENCER)Proof-of-concept data in both trials of EO2401 have demonstrated